Mitiglinide Calcium（KAD-1229 anhydrous）是一种胰岛素促分泌剂，通过拮抗ATP敏感性钾通道（KATP通道）发挥作用。该化合物对胰腺β细胞上的Kir6.2/SUR1复合物构成的特异性KATP通道具有高度选择性，在2型糖尿病的研究中具有重要价值。
|
英文别名 (English Synonym) |
Mitiglinide Calcium |
|
中文名称 (Chinese Name) |
米格列奈钙 |
|
靶点 (Target) |
Potassium Channel |
|
通路 (Pathway) |
Membrane Transporter/Ion Channel |
|
CAS号 (CAS NO.) |
145525-41-3 |
|
分子式 (Formula) |
C38H48CaN2O6 |
|
分子量 (Molecular Weight) |
668.88 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Sunaga Y, Gonoi T, Shibasaki T, Ichikawa K, Kusama H, Yano H, Seino S. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001 Nov 9;431(1):119-25. doi: 10.1016/s0014-2999(01)01412-1. PMID: 11716850. [2] Ichikawa K, Yamato T, Ojima K, Tsuji A, Ishikawa K, Kusama H, Kojima M. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol. 2002 May-Jun;29(5-6):423-7. doi: 10.1046/j.1440-1681.2002.03682.x. PMID: 12010187.
